MedTrace Logo

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT03041038 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-08-25

Study results available
· View outcomes & findings →

Summary

The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life.

Conditions

  • Ichthyosis
  • Autosomal Recessive Congenital Ichthyosis
  • Lamellar Ichthyosis
  • Congenital Ichthyosiform Erythroderma
  • Epidermolytic Ichthyosis
  • Netherton Syndrome

Interventions

DRUG

Secukinumab

Anti IL-17A antibody

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Amy Paller, MD · Northwestern University Department of Dermatology

  • Emma Guttman-Yassky, MD, PhD · Mt. Sinai Hospital Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03041038 on ClinicalTrials.gov